Pancreatic and gut hormones as predictors of new-onset prediabetes after non-necrotising acute pancreatitis: a prospective longitudinal cohort study

• Main Authors: Sakina H Bharmal, Wandia Kimita, Juyeon Ko, Maxim S Petrov
• Format: Article
• Language: English
• Published: Bioscientifica 2021-07-01
• Series: Endocrine Connections
• Subjects: pancreatitis; insulin; glucagon; new-onset prediabetes; prediction; prospective cohort study
• Online Access: https://ec.bioscientifica.com/view/journals/ec/10/7/EC-21-0229.xml

Objective: Early identification of individuals at high risk for metabolic derangements after an attack of acute pancreatitis (AP) is critical with a view to tertiary preventing of this disease. The aim was to investigate whether fasting pancreatic and gut hormones at baseline were predictive of future risk of new-onset prediabete s after acute pancreatitis (NOPAP) in individuals with non-necrotising AP. Methods: This was a prospective longitudinal cohort study that included 69 consecutive non-diabetic participants with AP, of whom 55% (n = 38) had normoglycaemia both at baseline and during follow-up, 25% (n = 17) had prediabetes both at baseline and during follow-up, and 20% (n = 14) were normoglycaemic at baseline but developed NOPAP during follow-up. The associations between the study groups and circulating fasting levels of pancreatic and gut hormones (insulin, glucagon, C-peptide, amylin, glucose-dependent insulinotropic peptide, glucagon-like peptide-1, pancreatic polypeptide, and peptide YY) were studied using multinomial regression in both unadjusted and adjusted analyses. Results: Elevated plasma insulin and glucagon at baseline were significa ntly associated with NOPAP (adjusted odds ratio 1.99, 95% CI 1.01 to 3.92 and a djusted odds ratio 3.44, 95% CI 1.06 to 11.19, respectively). The same hormones had no s ignificant association with antecedent prediabetes in AP. The other studied hormones w ere not significantly associated with the study groups. Conclusions: Normoglycaemic AP individuals with elevated fasting levels of insulin and glucagon at baseline constitute a high-risk group for future NO PAP.